Immunotherapy Combined With Chemotherapy Extends Survival in Advanced SMARCA4-Deficient Lung Cancer
A real-world retrospective study demonstrates that adding first-line immunotherapy to chemotherapy significantly prolongs median overall survival by 23 months in ...




















